New eye drops offer hope for dry eye sufferers unrelieved by artificial tears
NCT ID NCT07463950
First seen Mar 15, 2026
Summary
This study looks at whether a new cyclosporin eye drop (Vevizye®) can reduce inflammation and dryness in people with moderate to severe dry eye disease who still have symptoms after using artificial tears. About 25 adults with chronic dry eye and visible eye redness will use the drops for 12 weeks. The goal is to see if the drops improve comfort and eye appearance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Clinical Pharmacology, Medical University of Vienna, Austria
RECRUITINGVienna, State of Vienna, 1090, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can acne drug harm the eyes? new study investigates
- Which eye drop wins the dry eye battle? a Head-to-Head test
- Can a new eye drop soothe dry eye? a trial puts TRYPTYR to the test
- New eye drop aims to soothe dryness after cataract surgery
- Can simple eye drops soothe dry eyes? new study puts OTC brands to the test
- New eye drop hopes to soothe dry eye sufferers